|Bid||7.80 x 1000|
|Ask||7.89 x 900|
|Day's Range||7.79 - 8.39|
|52 Week Range||0.52 - 19.40|
|Beta (3Y Monthly)||8.43|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.25|
Further expanding its global IP portfolio, Microbot Medical Inc. (Nasdaq CM: MBOT) received an official communication from the European Patent Office regarding its intention to grant European Patent Application No. 13 746 563, which covers an adjustable guidewire for use in percutaneous coronary artery disease procedures. “As pioneers in the micro-robotic medical space, it is extremely encouraging to see that global regulatory bodies continue to recognize and provide protections for our novel technologies,” commented Harel Gadot, CEO, President and Chairman. “We believe these significant barriers to entry provide us with protections as we continue to monetize our investments and maximize shareholder value.
Microbot Medical Inc. (Nasdaq CM: MBOT) is maintaining its milestone targets for 2019 following the recently announced decision of the New York State Supreme Court to rescind the Stock Purchase Agreement (“SPA”) Microbot entered into with two affiliated investors in connection with its June 2017 Registered Direct Offering of approximately $10 million of common stock. The rescission would require the investors to transfer back to Microbot the shares they purchased in that offering, and Microbot to return to those investors their purchase price of $3.375 million.
Premier Health Group (OTC:PHGRF) (CSE:PHGI), Lipocine Inc., (LPCN), Microbot Medical Inc., (MBOT), and Capricor Therapeutics Inc., (CAPR) represent four healthcare companies determined to invest in the betterment of healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with up and coming technologies for the healthcare industry to create optimal care solutions for their patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI) today announced that the Company is moving forward with a binding Letter of Intent to a acquire two Metro Vancouver-based pharmacies.
Microbot Medical Inc. (MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it has entered into definitive agreements with institutional investors for the purchase of 250,000 shares of its common stock, at a purchase price per share of $10.00, in a registered direct offering priced at-the-market. Additionally, Microbot has agreed to issue to the investors unregistered warrants to purchase up to 250,000 shares of common stock.. The warrants have an exercise price of $10.00 per share of common stock, will be exercisable immediately and will expire one year from the issuance date. The gross proceeds to Microbot, before deducting placement agent fees and other offering expenses, are expected to be approximately $2.5 million.
Premier Health Group (PHGRF) (PHGI), Microbot Medical Inc (MBOT), eHealth Inc (EHTH), and Regional Health Properties Inc (NYSE American: RHE) represent four healthcare companies determined to invest in the future wellbeing of consumers. Premier Health Group (PHGRF) (PHGI) is a company focused on redesigning how medical care is received and implementing nuanced practical applications for cannabis products in the healthcare space. Premier Health Group (PHGRF) (PHGI) announced towards the end of last week that, in an effort to further its international expansion strategy, it has entered into a strategic partnership with China's 360 Health, a healthcare subsidiary of 360 Security Technology.
A look at the shareholders of Microbot Medical Inc. (NASDAQ:MBOT) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders Read More...
Microbot Medical Inc. (Nasdaq CM: MBOT) demonstrated an activated Self-Cleaning Shunt (SCSTM) during recent one-on-one investor and analyst meetings in San Francisco, which took place during the same week as the JP Morgan Healthcare conference. “Following our recent successful lab and pre-clinical testing of the SCSTM, coupled with the progress we made with the development of our SCSTM device, we are pleased to see the enormous interest and positive feedback from the professional community as we start exposing them to the device,” commented Harel Gadot, President, Chief Executive Officer and Chairman of Microbot. Dr. McAllister’s presentation was titled “Biocompatibility of the Novel Microbot Medical SCSTM Shunt Catheter” and was part of the Company’s participation at the annual meeting.
CORAL GABLES, FL / ACCESSWIRE / January 16, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Microbot Medical Inc (MBOT), Kitov Pharma Ltd (KTOV), and Teladoc Health Inc (TDOC) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients.
Massachusetts-based medical device developer Microbot Medical Inc. Microbot Medical -- which specializes in so-called "micro-robotic" medical technology -- said that an institutional investor is buying 455,323 shares of its common stock at $6.50 each. The deal is slated to wrap up Wednesday, with H.C. Wainwright & Co. acting as the exclusive placement agent for the offering.
Shares of medical device company Microbot Medical Inc. shot up 89% on Tuesday after it said it had validated the operational effectiveness of a self-cleaning shunt for treatment of hydrocephalus in an independent in-vitro laboratory study. Hydrocephalus is a condition in which excess cerebral spinal fluid in the brain's ventricles causes increased pressure that can result in damage to brain tissue. About an hour after that announcement, the company unveiled a $3 million registered direct offering priced-at-the-market for a purchase price of $6.50 a share. At 2.00 p.m. Eastern, it announced another stock offering, this time of $5.9 million of priced-at-the-market shares priced at $10. The stock has come off its highs and is now trading up 28%. The S&P 500 is up 0.7%.
Microbot Medical Inc. (MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 590,000 shares of its common stock, at a purchase price per share of $10.00, in a registered direct offering priced at-the-market. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to Microbot, before deducting placement agent fees and other offering expenses, are expected to be approximately $5.9 million.
Even after a 308% jump yesterday and a further 33% gain as of this afternoon, Microbot Medical Inc. (NASDAQ: MBOT) stock is trading around $13.05 but has a market capitalization of just $40 million. Plus, with only 2.79 million shares of MBOT stock outstanding and 26% of its float being sold short, MBOT is either an easy four-bagger or a stock that will lose all of those gains in no time. ### Why Microbot Medical Stock Rose An independent in-vitro laboratory study validated Microbot's self-cleaning shunt (or SCS). The theory that SCS may eventually treat occlusion, or Traumatic Brain Injury, is coming closer to reality. * 8 Dividend Stocks With Growth on the Horizon The contract-research-services firm that carried out the study used glioblastoma cells from human brains to assess the performance of SCS. During the 30-day study, the firm had three main findings,according to Microbot : InvestorPlace - Stock Market News, Stock Advice & Trading Tips * Significant cell growth and accumulation in a non-operating SCS and * A significant inhibition in cell growth in the constantly operating SCS with very little to no cell attachment on the robotic brush (ViRob) and on the opening where the robotic brush (ViRob) operates. * The study also demonstrated that the Company's SCS has the ability to operate after cells had accumulated on the catheter holes and the robotic brush (ViRob). Importantly, multiple, previous clinical studies have found that declines of memory that occur after head injuries can be prevented by slowing the growth of brain cells. ### Platforms And Products That Could Boost MBOT Stock ViRob is one of the company's two main platforms. It's a miniature robot that moves around inside of the human body. ViRob can be controlled remotely and fits in blood vessels, the digestive tract and the respiratory system. If the study of SCS validates its clinical use, then it may be used to treat a number of ailments. Among the conditions that SCS could treat, according to MBOT, are hydrocephalus, or "water in the brain," which occurs in 1 in every 500 babies born in the U.S., and normal pressure hydrocephalus (NPH), which can occur after a head injury. It is estimated that over 700,000 Americans have NPH. The other main platform, TipCAT, is a flexible endoscope that may help doctors treat problems that occur within the body's tubular structures, including the colon, blood vessels, and the urinary tract. Finally, the Tip Catheter Colonoscope, or TCC, product could be used to facilitate endoscopies, a procedure that is done 15 million to 20 million times annually. If one or more of these products are approved by the FDA and then widely adopted, MBOT stock is likely to rally tremendously. ### Related Investments Investors who are interested in the biotechnology and medical-equipment sector can invest in names other than MBOT stock. Exact Sciences Corporation (NASDAQ: EXAS) is growing nicely, thanks to its Cologuard test, a product which screens for colon cancer. Approved by the FDA in August 2014, the product was recommended by the American Cancer Society. The company estimated that it generated total revenue of $454 million to $455 million last year, up 71% year-over-year. Medtronic plc (NYSE: MDT) is a medical appliances and equipment supplier and is far more established than Microbot. Its shares are down about 14% from their 52-week highs and are valued at 15.6 times MDT's forward price-earnings ratio, which is based on analysts' consensus 2019 earnings-per-share estimate. Medtronic stock fell recently because of worries over its acquisition of Covidien. This acquisition widens the company's market because Covidien makes products that are used by hospitals to provide acute care. Conversely, Medtronic's product portfolio focuses primarily on chronic diseases. ### The Bottom Line on MBOT Stock MBOT stock may or may not drop from its current levels. No one knows for sure. And yet , MBOT stock is still more than 50% below the level it reached in April 2016, when MBOT stock was trading around $36. Those who bought Microbot Medical stock at $5.00 or less are enjoying their tremendous gains, while those who were on the sidelines might want to watch MBOT stock for awhile before buying it. As of this writing, the author did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Companies That Could Post Decelerating Profits * 10 A-Rated Stocks the Smart Money Is Piling Into * Mizuho: 7 Long-Term Value Stocks to Buy Now Compare Brokers The post Microbot's Products in Focus After Huge Gains by MBOT Stock appeared first on InvestorPlace.
Microbot Medical Soars on Encouraging Study DataStock price soarsToday, Microbot Medical (MBOT) announced a registered direct offering worth $3 million at $6.50 per share, and yesterday, the company announced results demonstrating the operational
Microbot Medical Inc. (MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it has entered into a definitive agreement with an institutional investor for the purchase of 455,323 shares of its common stock (or common stock equivalents), at a purchase price per share of $6.50, in a registered direct offering priced at-the-market. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to Microbot, before deducting placement agent fees and other offering expenses, are expected to be approximately $3.0 million.
In the latest Microbot Medical news (NASDAQ:MBOT), the company's stock went absolutely gangbusters as it soared more than 300% by day's end Monday following "highly encouraging" study results. Source: Images Money via Flickr (Modified) The study in question is examining the efficacy of the Newark, California-based biopharmaceutical company's Self-Cleaning Shunt (SCS), which is designed to treat hydrocephalus. The condition in question is a buildup of fluid in the cavities that are located deep within the brain. Hydrocephalus causes the excess fluid to increase the size of the ventricles, which puts pressure on the brain. "We believe the performance of the SCS during this and previous studies gives us greater confidence to explore additional medical applications for the device in conditions where occlusion occurs, such as in the Traumatic Brain Injury (TBI) space," Microbot Medical CEO Harel Gadot said in a statement. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The condition essentially consists of an imbalance in how much cerebrospinal fluid is produced and absorbed into a person's bloodstream. This imbalance is harmful due to cerebrospinal fluid's key role in optimizing brain function by protecting it from injury, keeping it buoyant, removing waste from the brain's metabolism and more. MBOT stock had a day to remember as the stock shot up a whopping 307.9% by the end of trading, with shares now selling for $9.79 apiece. The stock surged an additional 16.3% after the bell Monday. ### More From InvestorPlace * Morgan Stanley: 7 Risky Stocks to Sell Now * 10 Stocks You Can Set and Forget (Even In This Market) * The 7 Best Stocks in the Entrepreneur Index Compare Brokers The post Microbot Medical News: Why MBOT Stock Is Skyrocketing Today appeared first on InvestorPlace.
CORAL GABLES, FL / ACCESSWIRE / January 14, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Microbot Medical Inc (MBOT), Valeritas Holdings Inc (VLRX), and Opko Health Inc (OPK) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients.
Microbot Medical (MBOT) announced today that it has validated the operational effectiveness of the Company’s Self-Cleaning Shunt (SCSTM) in a recent independent in-vitro laboratory study. The Company also shared images of its SCSTM from the laboratory study that clearly demonstrate the device prevented shunt occlusion. “We believe the highly encouraging results from this latest study, which complements our previous pre-clinical studies, demonstrates the potential of our SCSTM product to revolutionize how Hydrocephalus and Normal Pressure Hydrocephalus (NPH) can be treated in the future,” commented Harel Gadot, CEO, President and Chairman.
Microbot Medical Inc. (MBOT), received a notification from the European Patent Office that it will grant a patent for Application No. 08738207, which covers the Company’s ViRob™ technology platform. Including this latest notification, the Company has 30 issued/allowed patents and 18 patent applications pending worldwide. “The allowance of this European patent application further strengthens our global intellectual property estate covering micro-robotic technology platform,” commented Harel Gadot, CEO, President and Chairman.
Microbot Medical Inc. (Nasdaq CM: MBOT) announced today anticipated operational and product milestones, including pivotal pre-clinical study and FDA pre-submission milestones, for 2019. The progress and successful execution of key objectives in 2018, which included, among other things, Microbot’s successful completion of the first phase of the ongoing pre-clinical trials, the expansion of Microbot’s portfolio of technologies and intellectual property and the strengthening of Microbot’s management team to meet the next phase of the Company’s development efforts, are expected to position Microbot to achieve the milestones listed below during 2019.